Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.4 USD | +2.64% |
|
+8.66% | -20.43% |
Jul. 01 | Pediatrix Medical Group, Inc.(NYSE:MD) dropped from Russell 2000 Value-Defensive Index | CI |
Jul. 01 | Pediatrix Medical Group, Inc.(NYSE:MD) dropped from Russell 2000 Defensive Index | CI |
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The stock, which is currently worth 2024 to 0.52 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.43% | 613M | B | ||
+19.84% | 84.94B | C+ | ||
-25.24% | 74.07B | B- | ||
-1.34% | 26.15B | C+ | ||
+4.56% | 18.03B | A- | ||
-9.29% | 17.38B | B | ||
+4.52% | 16.01B | A- | ||
+78.16% | 13.7B | C- | ||
+77.84% | 13.13B | C+ | ||
-26.14% | 12.74B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MD Stock
- Ratings Pediatrix Medical Group, Inc.